华昊中天医药-B 02563Stock Information

Stock Information · Old Rules
// Company Overview //
Stock Name华昊中天医药-B
Stock Code02563
Company Full Name华昊中天医药-B
Industry醫療保健
Principal Activities公司是由留美科學家團隊創立的國家級高新技術企業,依托先進且可持續的合成生物學新藥研發平臺,專注于開發具有自主知識產權的抗癌新藥,經過20余年的發展,公司已成為集新藥研發、生產和商業化為一體的整合型生物醫藥公司。
Listing Date2024-10-31
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市北京經濟技術開發區亦城財富中心B座1202室
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttps://www.biostar-pharm.com/
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo
// Offering Information //
Offering Mechanism 未知
Clawback TiersNo data
Prospectus Date2024-10-23
Offer PriceHK$ 16.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 3,200
Par ValueNo data
Global Offering Shares14,588,000
HK Public Offering Shares— (0.0%)
International Placing Shares— (0.0%)
Offer RatioNo data
Total Shares Post-IPONo data
Total Global Offering SizeHK$ 233,408,000
Public Offering SizeHK$ — (0.0%)
Oversubscription Multiple21.4x
Valid Applications7,175
Accepted Applications1,971
ReallocationNo
Total Funds RaisedHK$ 28,009,600
Greenshoe (Over-allotment Option)No
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
Pre-IPO Valuation (Last Round)No data
P/E Ratio-28.06
Profit/Loss StatusNo data
Period-End Cash BalanceNo data
Listing Expenses~HK$ 37,520,000
Listing Expenses / Funds RaisedNo data
Total Pre-IPO InvestmentNo data
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 21.5
First Day Change30.00%
First Day Volume3185800.0
First Day Turnover69538800.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約44.9%或105.1百萬港元,將用于資助核心產品的進行中及計劃進行的臨床試驗; 2、約38.9%或91.1百萬港元,將用于資助核心產品以外的進行中及計劃進行的臨床試驗及產品臨床前研究以及核心產品研究者發起的試驗; 3、約3.0%或7.0百萬港元,將用于加強公司的國內商業化能力及建立公司的全球營銷網絡; 4、約3.2%或7.4百萬港元,將用于擴大產能; 5、約10.0%或23.4百萬港元,將用作營運資金及一般公司用途。
// Underwriting Syndicate //
联席保荐人 (2)
建银国际金融有限公司 中信建投(国际)融资有限公司
整体协调人 (2)
建银国际金融有限公司 中信建投(国际)融资有限公司
联席账簿管理人 (16)
建银国际金融有限公司 中信建投(国际)融资有限公司 工银国际证券有限公司 民银证券有限公司 浦银国际融资有限公司 中国银河国际证券(香港)有限公司 申万宏源证券(香港)有限公司 中泰国际证券有限公司 东方证券(香港)有限公司 复星国际证券有限公司 国元证券经纪(香港)有限公司 山证国际证券有限公司 第一上海证券有限公司 百惠证券有限公司 海盈证券有限公司 巨诚证券有限公司
联席牵头经办人 (17)
建银国际金融有限公司 中信建投(国际)融资有限公司 工银国际证券有限公司 民银证券有限公司 浦银国际融资有限公司 中国银河国际证券(香港)有限公司 申万宏源证券(香港)有限公司 中泰国际证券有限公司 东方证券(香港)有限公司 复星国际证券有限公司 国元证券经纪(香港)有限公司 山证国际证券有限公司 第一上海证券有限公司 百惠证券有限公司 海盈证券有限公司 巨诚证券有限公司 富途证券国际(香港)有限公司
// Cornerstone Investors //
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Novotech SG Holdings Pte. Ltd. 23,081,600 HKD 9.89% 6 months 2025-04-30
2 Silky Water Absolute Return LPF 61,555,200 HKD 26.37% 6 months 2025-04-30
3 百洋健康产业国际商贸有限公司 15,376,000 HKD 6.59% 6 months 2025-04-30
4 富策控股有限公司 77,721,600 HKD 33.30% 6 months 2025-04-30
// Directors & Management //
Chairman唐莉
Company Secretary劉開林,陳奕斌
No director data available.
// Major Shareholders //
Major Shareholders & HoldingsBaygen QT Inc.(11.11%),珠海京蓉昊緣投資合伙企業(有限合伙)(5.59%),珠海華錦昊緣企業管理合伙企業(有限合伙)(5.27%)
// Allotment Benchmarks //
Pool A (Small Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
200 2,900 129 0.04
400 1,006 89 0.09
600 356 47 0.13
800 182 32 0.18
1,000 440 94 0.21
1,200 102 26 0.26
1,400 69 20 0.29
1,600 72 23 0.32
1,800 81 29 0.36
2,000 569 225 0.40
3,000 196 116 0.59
4,000 276 217 0.79
5,000 119 117 0.98
6,000 91 16 1.18
7,000 33 12 1.36
8,000 45 24 1.53
9,000 26 18 1.69
10,000 268 236 1.88
20,000 154 117 3.76
30,000 45 26 5.58
40,000 33 14 7.42
50,000 30 8 9.28
60,000 14 2 11.13
70,000 4 4 12.98
80,000 6 4 14.68
90,000 4 2 16.51
100,000 13 3 18.25
150,000 6 2 27.30
200,000 9 4 36.40
250,000 13 6 131.50
300,000 7 2 157.35
Pool B (Large Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
400,000 1 1 209.00
450,000 1 1 234.90
500,000 1 1 261.00
550,000 3 3 287.10
Allotment Benchmarks
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics